A Randomized Controlled Study on the Effect of Supplementing Fibrinogen on Coagulation Function After Double Plasma Exchange Using Albumin as Replacement Fluid, and Its Safety and Effectiveness

INTERVENTION: Traditional DFPP group:Received routine treatment only, without additional infusion of human fibrinogen;DFPP + Fibrinogen Group:Intravenous infusion of 2–3 g human fibrinogen immediately after DFPP treatment; CONDITION: Blood transfusion‐related side effects PRIMARY OUTCOME: Incidence of coagulation dysfunction; SECONDARY OUTCOME: Incidence of filter failure;Changes in coagulation function indicators before and after treatment;Volume of blood transfusion after treatment;Changes in Sequential Organ Failure Assessment (SOFA) score;Bleeding events;Incidence of drug allergy to human fibrinogen; INCLUSION CRITERIA: 1. Age = 18 years; 2. Patients who meet the clinical indications for DFPP and are scheduled to undergo DFPP; 3. Patients scheduled to receive double filtration plasmapheresis with albumin as the replacement fluid; 4. Voluntary participation in this study and signed informed consent.